Person: SÜMBÜL, BİLGE
4 results
Search Results
Now showing 1 - 4 of 4
Publication Open Access Humoral Response to BNT162b2 and CoronaVac in Patients Undergoing Maintenance Hemodialysis: A Multicenter Prospective Cohort Study.(2023-01-05) Mirioglu S.; Kazancioglu R.; Cebeci E.; Eren N.; Sakaci T.; Alagoz S.; Tugcu M.; Tuglular S.; Sumbul B.; Seyahi N.; et al.; SÜMBÜL, BİLGEPublication Metadata only Thorax computed tomography findings and anti-SARS-CoV-2 immunoglobulin G levels in polymerase chain reaction-negative probable COVID-19 cases.(2022-11-25) Yurtsever I.; Karatoprak C.; Sumbul B.; Kiskac M.; Tunc M.; Zorlu M.; Ogun H.; Durdu B.; Toluk O.; Cakirca M.; YURTSEVER, İSMAİL; KARATOPRAK, CUMALİ; SÜMBÜL, BİLGE; KISKAÇ, MUHARREM; TUNÇ, MUHAMMED; ZORLU, MEHMET; OGUN, HAMZA; DURDU, BÜLENT; TOLUK, ÖZLEM; ÇAKIRCA, MUSTAFAOBJECTIVE: This study aimed to evaluate the SARS-CoV-2 immunoglobulin G (IgG) levels after 6 months of polymerase chain reaction (PCR) negativebut assumed to be COVID-19 positive cases to investigate the relationship between IgG levels and thoracic computed tomography (CT) findings.METHODS: This was a single-center study that included patients whose PCR test results were negative at least three times using nasopharyngealswabs but had clinical findings of COVID-19 and thoracic CT findings compatible with viral pneumonia. Six months after discharge, the IgG antibodieswere analyzed. The cutoff value for negative and positive serology was defined as <1.4 (index S/C) and ≥1.4 (index S/C), respectively. In addition, thepatients were categorized according to their thoracic CT findings as high (typical) and low (atypical). Also, the patients were grouped into classes as<5% lung involvement versus ≥5% lung involvement.RESULTS: The patients’ mean age was 49.78±12.96 years. PCR was negative, but patients with COVID-19 symptoms who had SARS-CoV-2 IgGpositive were 81.9% (n=95). The antibody titer and lung involvement ≥5% were statistically significantly higher in SARS-CoV-2 IgG positive cases(p<0.001 and p=0.021). Age and chest CT findings were the risk factors for lung involvement (OR=1.08, p<0.001 and OR=2.19, p=0.010, respectively).CONCLUSION: This study is valuable because increasing severity (≥5%) of lung involvement appears to be associated with high and persistent IgGantibody titers. In probable cases of COVID-19, even if the PCR test is negative, high IgG titers 6 months after discharge can predict the rate of lungparenchymal involvement.Publication Open Access Altered gut microbiota in patients with idiopathic Parkinson’s disease: an age–sex matched case–control study(2023-01-01) Babacan Yildiz G.; Kayacan Z. C.; KARACAN İ.; SÜMBÜL B.; Elibol B.; Gelisin O.; Akgul O.; BABACAN YILDIZ, GÜLSEN; SÜMBÜL, BİLGE; GELİŞİN, ÖZLEMObjective: The investigations related to how gut microbiota changes the brain-gut axis in idiopathic Parkinson's disease (PD) attract growing interest. We aimed to determine whether gut microbiota is altered in PD patients and whether non-motor symptoms of PD and disease duration had any relation with alterations of microbiota profiles among patients. Methods: Microbial taxa in stool samples obtained from 84 subjects (42-PD patients and 42-healthy spouses) were analyzed using 16S rRNA amplicon-sequencing. Results: We observed a significant decrease of Firmicutes and a significant increase of Verrucomicrobiota at the phylum level. At the family level, Lactobacillaceae and Akkermansiaceae were significantly increased and Coriobacteriales Incertae Sedis were significantly decreased in the PD patients compared to their healthy spouses. Genus level comparison inferred significant increase in abundance only in Lactobacillus while the abundance of Lachnospiraceae ND3007 group, Tyzzerella, Fusicatenibacter, Eubacterium hallii group and Ruminococcus gauvreauii group were all decreased. We determined that the abundance of Prevotella genus decreased, but not significantly in PD patients. In addition, we found differences in microbiota composition between patients with and without non-motor symptoms. Conclusion: We observed differences in gut microbiota composition between PD patients and their healthy spouses. Our findings suggest that disease duration influenced microbiota composition, which in turn influenced development of non-motor symptoms in PD. This study is the first in terms of both gut microbiota research in Turkish PD patients and the probable effect of microbiota on non-motor symptoms of PD.Publication Metadata only Results of nucleos(t)ide analog treatment discontinuation in hepatitis b e-Antigen-negative chronic hepatitis b: Nucstop study(2024-01-01) Kiremitci S.; Kochan K.; SEVEN G.; Keskin E. B.; OKAY G.; AKKOYUNLU Y.; Koc M. M.; SÜMBÜL B.; ŞENTÜRK H.; KİREMİTÇİ, SERCAN; KOÇHAN, KORAY; SEVEN, GÜLSEREN; OKAY, GÜLAY; AKKOYUNLU, YASEMİN; SÜMBÜL, BİLGE; ŞENTÜRK, HAKANBackground/Aims: This study aims to investigate the effects of nucleos(t)ide analogs (NAs) discontinuation in eligible patients in accordance with the Asian Pacific Association for the Study of the Liver hepatitis B guideline and the factors affecting clinical and virological relapses. Materials and Methods: In this prospectively designed study, hepatitis B e antigen (HBeAg)-negative chronic hepatitis B patients who were followed up between 2012 and 2019 were evaluated and 57 patients were included. All participants enrolled the study were HBeAgnegative status at NA initiation. Results: The median age of the patients was 49 (29-72) years and 24 (42%) were females. The median treatment duration was 96 (36-276) months and patients were followed for a median duration of 27 months. Sixteen patients had a previous history of NA switch, and thirteen of these patients had a history of lamivudine resistance. Thirty-eight of 57 patients (66%) developed an elevated hepatitis B virus deoxyribonucleic acid level of 2000 IU/mL at least once, defined as virological relapse and 23 (60%) of them, experienced clinical relapse. Thirty-one of 57 patients were re-Treated during the follow-up, and hepatitis B surface antigen (HBsAg) loss occurred among 4 (7%) patients. All patients who experienced HBsAg loss had a history of lamivudine resistance (P = .002). Conclusion: Despite receiving NAs suppression therapy for a long time, HBsAg loss occurs rarely. Although it was not life-Threatening, most patients experienced relapses and treatment should be restarted. In our study, whether it is a coincidence that all patients with HBsAg loss are patients in whom NAs are used sequentially due to lamivudine resistance is an issue that needs to be further investigated.